High-Value Cancer Care and the Problem With Surrogate Endpoints in the Quality/Cost Equation

Author: Fumiko Chino MD
View More View Less
Restricted access
  • 1.

    Schnipper LE, Davidson NE, Wollins DS, Updating the American Society of Clinical Oncology Value Framework: revisions and reflections in response to comments received. J Clin Oncol 2016;34:29252934.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Cheng S, Cheung MC, Jiang DM, Are surrogate endpoints unbiased metrics in clinical benefit scores of the ASCO Value Framework? J Natl Compr Canc Netw 2019;17:1489–1496.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Kim C, Prasad V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern Med 2015;175:19921994.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Chen EY, Raghunathan V, Prasad V. An overview of cancer drugs approved by the US Food and Drug Administration based on the surrogate end point of response rate. JAMA Intern Med 2019;179:915921.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Chen EY, Joshi SK, Tran A, Prasad V. Estimation of study time reduction using surrogate end points rather than overall survival in oncology clinical trials. JAMA Intern Med 2019;179:642647.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Haslam A, Hey SP, Gill J, Prasad V. A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology. Eur J Cancer 2019;106:196211.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Kay A, Higgins J, Day AG, Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points. Ann Oncol 2012;23:16461651.

  • 8.

    Saluja R, Everest L, Cheng S, Assessment of whether the American Society of Clinical Oncology's Value Framework and the European Society for Medical Oncology's Magnitude of Clinical Benefit Scale measure absolute or relative clinical survival benefit: a meta-analysis of randomized clinical trials [published online May 16, 2019]. JAMA Oncol. doi: 10.1001/jamaoncol.2019.0818

    • Search Google Scholar
    • Export Citation
  • 9.

    Seymour EK, Schiffer CA, de Souza JA. Challenges in the clinical application of the American Society of Clinical Oncology Value Framework: a Medicare cost-benefit analysis in chronic lymphocytic leukemia. J Oncol Pract 2017;13:e10021011.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Saad ED, Buyse M. Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents. Ann Oncol 2016;27:373378.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1013 1013 14
PDF Downloads 166 166 6
EPUB Downloads 0 0 0